Archives

New Alzheimer’s drug slows cognitive decline by 35 per cent

4 May 2023

A clinical trial has revealed a new Alzheimer’s drug can successfully slow down decline in memory and thinking by 35 per cent. Donanemab has been shown to significantly reduce cognitive decline in people with early-stage Alzheimer’s disease. The trial by US pharmaceutical company Eli Lilly showed it has been successful in removing sticky amyloid plaques […]

Dementia lead welcomes appointment of new chairs to mission

21 March 2023

The Government has announced two leaders in dementia research will co-chair a national mission dedicated to tackling the condition. Hilary Evans and Nadeem Sarwar have been appointed to the Dame Barbara Windsor Dementia Mission, following an announcement by George Freeman, the Minister for Science, Research and Innovation at the World Dementia Council Summit this week. […]

Dementia during COVID-19 – the lived experience perspective

10 November 2022

A Scottish study which recruited participants through Join Dementia Research has published their findings on the effects of the adapted dementia diagnosis and consultation processes during the COVID-19 pandemic. The research has been co-produced by the University of Edinburgh and the Better Understanding Dementia Diagnosis (BUDDs) lived experience group, and funded by UK Research and […]

Investigating the impact of anti-inflammatory drugs on Alzheimer’s disease

18 October 2022

A research study exploring the impact specialist anti-inflammatory drugs have on Alzheimer’s disease symptoms is looking for volunteers in London, Plymouth, Guildford and Southampton. The EXploratory PLatform trial on Anti-INflammatory agents in Alzheimer’s Disease, or EXPLAIN-AD for short, will be evaluating the effectiveness and safety of anti-inflammatory agents on common Alzheimer’s symptoms – including memory, […]

Lecanemab – a potential new treatment for Alzheimer’s disease

28 September 2022

News that a potential treatment for early stage Alzheimer’s disease can slow cognitive decline is a significant development in dementia research. About the drug Lecanemab is an antibody that is designed to remove toxic beta-amyloid deposits; proteins that build up in the brains of people with Alzheimer’s disease. Following phase 3 clinical trials, pharmaceutical companies […]

Diabetes drug to be tested as a potential treatment for Alzheimer’s disease

7 September 2022

Clinical trials across England and Scotland are underway to investigate if an existing diabetes medicine can potentially work as a disease-modifying option for early-stage Alzheimer’s disease. Novo Nordisk is now working alongside Join Dementia Research to investigate if the medicine, known as semaglutide, could also benefit people living with early Alzheimer’s disease. What the study […]

Could an anti-sickness drug treat hallucinations?

16 August 2022

A national research study is investigating whether a readily available anti-sickness drug could treat dementia-related hallucinations. The Trial of Ondansetron as a Parkinson’s HAllucinations Treatment, or TOP HAT study, is recruiting volunteers across England, Scotland and Wales to evaluate whether ondansetron, an anti-sickness drug used in the NHS, could also be used for treating hallucinations […]

New volunteers sign up as Prime Minister launches national dementia mission

15 August 2022

On 14 August 2022, the Prime Minister launched a national mission to tackle dementia in memory of the late Dame Barbara Windsor. He called for volunteers to join ‘Babs’ Army’ and sign up to Join Dementia Research. Since then we’ve welcomed hundreds of new people to the service from all over the UK. About Join […]

Shaping the future of early-stage dementia support

19 July 2022

A pioneering international study is exploring how health promotion and self-management programmes could be used to support people with early-stage dementia and improve their health outcomes. The Self-management and HeAlth Promotion in early-stage dementia with E-learning for carers study, or SHAPE for short, is looking to recruit people with a mild to moderate dementia diagnosis […]

Clinical study to assess potential Alzheimer’s drug

13 July 2022

There are almost one million people with dementia in the UK and the most common cause is Alzheimer’s disease. Researchers from University College London (UCL) with funding from the National Institute for Health and Care Research are testing a new approach to the treatment of mild Alzheimer’s disease in the DESPIAD (DEpletion of SaP in […]

1 2 3 5
get_header(); ?>

Archives

1 2 3 5